title: Modification of primary and recurrent genital herpes in guinea pigs by passive immunization.
abstract: Guinea pigs were administered antiserum 24 h (As+24) or 72 h (As+72) after intravaginal herpes simplex virus type 2 (HSV-2) challenge. Treatment at either time reduced acute virus replication in the dorsal root ganglia and the overall magnitude of replication in the genital tract. In two studies, As+24 treatment significantly reduced the severity of primary genital skin disease and the frequency of subsequent spontaneous recurrent disease. In contrast, As+72 treatment produced a modest reduction in primary disease severity but did not impact on recurrent disease. Quantitative PCR analysis of dorsal root ganglia DNA from latently infected animals showed that As+24 treatment produced a significantly reduced viral DNA burden, which appeared to correlate with the reduction in recurrent disease. The amount of DNA in the ganglia of As+72-treated animals was not significantly lower than that of controls. These observations have implications for both the dynamics of latency establishment and desirable vaccine characteristics.
authors.affiliation: Children's Hospital Medical Center, Division of Infectious Diseases, 3333 Burnet Ave, Cincinnati, OH 45229-3039, USA1.
authors.forename: Nigel
authors.initials: N
authors.lastname: Bourne
authors.affiliation: Children's Hospital Medical Center, Division of Infectious Diseases, 3333 Burnet Ave, Cincinnati, OH 45229-3039, USA1.
authors.forename: Richard B
authors.initials: RB
authors.lastname: Pyles
authors.affiliation: Children's Hospital Medical Center, Division of Infectious Diseases, 3333 Burnet Ave, Cincinnati, OH 45229-3039, USA1.
authors.forename: David I
authors.initials: DI
authors.lastname: Bernstein
authors.affiliation: Children's Hospital Medical Center, Division of Infectious Diseases, 3333 Burnet Ave, Cincinnati, OH 45229-3039, USA1.
authors.forename: Lawrence R
authors.initials: LR
authors.lastname: Stanberry
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology*; D004279:DNA, Viral / Q000032:analysis; D004195:Disease Models, Animal; D005260:Female; D005724:Ganglia / Q000821:virology; D005727:Ganglia, Spinal / Q000821:virology; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D018258:Herpesvirus 2, Human / Q000276:immunology; D006801:Humans; D007116:Immunization, Passive; D011817:Rabbits; D014621:Vagina / Q000821:virology
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral